x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

PACUPod: Cardiology

Pharmacy & Acute Care University

PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across cardiology pharmacotherapy and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for

health & fitness medicine

All Episodes

8:15

Loop and thiazide diuretics and outcomes in heart...

PACUPod: Cardiology ·

2025/11/19

en

0:02

Early Cardiac Rehabilitation for Critically Ill...

PACUPod: Cardiology ·

2025/10/21

This PACUPod episode reviews Wu et al.'s randomized trial in JAMA Network Open evaluating early cardiac rehabilitation initiated during the CICU for patients with acute decompensated heart failure. In this single-center study of 120 high-risk CICU patients, participants were randomized to an early, progressive, personalized cardiac rehab program during CICU stay (AHF-CR) or to usual care without structured early rehab. Primary outcomes were discharge Short Physical Performance Battery

en

8:38

Remnant to LDL cholesterol discordance as a predictor...

PACUPod: Cardiology ·

2025/10/21

In this episode, hosts Britany and Seth unpack the prospective Murcia AF Project III (MAFP-III) cohort study, which investigates remnant cholesterol (RC) and LDL-C discordance as predictors of thromboembolic events in patients with atrial fibrillation on oral anticoagulation. They explain how RC reflects triglyceride-rich lipoproteins (VLDL/IDL), how RC is calculated from standard lipid panels (total cholesterol minus LDL-C minus HDL-C), and the main finding: elevated RC predicts higher

en

10:18

Antiplatelet Therapy in Myocardial Bridge Insights...

PACUPod: Cardiology ·

2025/10/21

Myocardial bridge (MB) is a common congenital coronary anomaly where a coronary artery tunnels through the myocardium, causing systolic compression. This PACUPod overview examines whether single antiplatelet therapy (APT), such as aspirin, provides ischemic protection for MB patients without other indications, and how the RIALTO registry informs clinical practice. The ambispective study analyzed 221 MB patients after excluding those with established APT or anticoagulation indications,

en

7:28

Impact of Body Mass Index Central Adiposity and...

PACUPod: Cardiology ·

2025/10/21

This PACUPod episode reviews a secondary analysis of the SUMMIT trial investigating how baseline adiposity (BMI and central adiposity via waist-height ratio) and weight loss influence tirzepatide's benefits in obesity-related HFpEF. The discussion covers study design, primary outcome (time to cardiovascular death or worsening heart failure), and secondary outcomes (KCCQ-CSS, six-minute walk distance, CRP, body weight, and systolic blood pressure). Tirzepatide reduced the primary endpoint

en

0:02

SodiumGlucose Cotransporter 2 Inhibitor With and...

PACUPod: Cardiology ·

2025/10/21

PACULit examines the SOGALDI-PEF trial, the first randomized crossover study comparing dapagliflozin alone versus dapagliflozin plus spironolactone in heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). The episode discusses the rationale for combining an SGLT2 inhibitor with a mineralocorticoid receptor antagonist, the primary NT-proBNP endpoint as a surrogate for cardiac stress, and key results showing an approximate 11% relative reduction in NT-proBNP with

en

6:31

Effect of P2Y12 Inhibitors on Major Adverse...

PACUPod: Cardiology ·

2025/10/21

This PACUPod episode summarizes Barry et al.'s population-based cohort study on the impact of post-CABG P2Y12 inhibitors (primarily clopidogrel) on major adverse cardiovascular events. Using data from British Columbia (2002–2020) involving over 15,000 adults undergoing isolated CABG, exposure was defined as filling a P2Y12 inhibitor prescription within 30 days after surgery, compared with aspirin alone or no antiplatelet therapy. The primary outcome was time to first MACE (all-cause death,

en

4:39

The effect of colchicine on coagulation in patients...

PACUPod: Cardiology ·

2025/10/21

A concise overview of a prospective controlled cohort study assessing whether adding low-dose colchicine (0.5 mg daily) to stable vitamin K antagonist (VKA) therapy in adults with chronic coronary disease affects anticoagulation control. Primary outcome: INR changes; secondary outcomes: VKA dose adjustments and time in therapeutic range (TTR). Findings: initiation, continuation, or withdrawal of low-dose colchicine did not significantly alter INR, VKA dosing, or TTR, supporting safe

en

7:28

Catheter Ablation vs Lifestyle Modification With...

PACUPod: Cardiology ·

2025/10/21

This PACULit episode reviews the PRAGUE-25 randomized multicenter noninferiority trial comparing catheter ablation with lifestyle modification plus guideline-directed antiarrhythmic drugs in adults with obesity (BMI 30–40) and paroxysmal or persistent atrial fibrillation. The ablation strategy focused on pulmonary vein isolation, while the lifestyle arm emphasized weight loss and physical activity paired with antiarrhythmic therapy. The primary endpoint—freedom from AF at 12 months (no

en

0:02

Proton Pump Inhibitor Use and Incident Hypertension...

PACUPod: Cardiology ·

2025/10/21

en

6:12

Effect of dapagliflozin on malignant ventricular...

PACUPod: Cardiology ·

2025/10/21

This PACULit update summarizes a single-center, prospective observational study (ChangZhou Registry) evaluating whether initiating dapagliflozin during hospitalization for acute myocardial infarction reduces malignant ventricular arrhythmias in elderly patients and affects all-cause mortality over about seven months. In 2,607 patients aged 60 and older with confirmed AMI, those treated with dapagliflozin were compared to standard care using propensity score matching. The primary outcome was

en

6:35

Risk of Acute Infections in New Users of...

PACUPod: Cardiology ·

2025/10/21

This PACULit episode reviews a large observational cohort study by Aebi et al. using UK CPRD data (2000–2021) to compare new monotherapy users of amlodipine, ramipril, and bendroflūmethylthiazide (bendroflumethiazide) and to assess risk of acute outpatient infections (respiratory, genitourinary, gastrointestinal, sepsis) and SARS-CoV-2 infection during 2020–2021. The primary comparisons were amlodipine versus ramipril and amlodipine versus bendroflumethiazide, with follow-up from

en

6:27

Relationship Between Neutrophil Count and 90 Day...

PACUPod: Cardiology ·

2025/10/21

en

7:36

Benefit and Harm of Intensive Blood Pressure Control...

PACUPod: Cardiology ·

2025/10/21

A concise episode summarizing a post hoc analysis of the STEP trial that investigates how baseline cardiovascular risk modifies the balance of benefits and harms of intensive blood pressure control in older hypertensive adults. We cover study design, key findings (overall reduction in cardiovascular events with intensive targets, modest non-significant rise in adverse events), risk-stratified results, practical targets (110–130 mm Hg vs 130–150 mm Hg), and implications for practice in

en

7:17

A Phase III Randomized Double-Blind Active-Controlled...

PACUPod: Cardiology ·

2025/10/21

en

7:00

Artificial Intelligence Enabled ECGs for Atrial...

PACUPod: Cardiology ·

2025/10/21

In this PACUPod episode, we review a pragmatic, cluster-randomized trial evaluating AI-assisted interpretation of standard 12-lead ECGs to identify atrial fibrillation and prompt guideline-directed oral anticoagulant therapy in hospitalized patients managed by non-cardiologists across two Taiwanese hospitals. The AI sends alerts with actionable recommendations to consider AF diagnosis and initiate NOACs. Primary outcomes include NOAC prescription within 90 days post-discharge, new AF

en

7:32

Efficacy and Safety of Edoxaban in Anticoagulant...

PACUPod: Cardiology ·

2025/10/21

This PACULit episode reviews a phase 3, randomized, open-label multicenter trial evaluating edoxaban started within three months after surgical bioprosthetic valve replacement (aortic and/or mitral) compared with warfarin. The primary outcome was stroke or systemic embolism; edoxaban showed 0.5% vs 1.5% in warfarin with a risk difference of −1.03% (95% CI −4.34% to 1.95%), indicating comparable efficacy. Major bleeding was higher with edoxaban (4.1% vs 1.0%; risk difference 3.07%, 95% CI

en

5:22

Transitions of Care Pharmacist Impact Following...

PACUPod: Cardiology ·

2025/10/21

In this PACUPod episode, the study by Augustine et al. on pharmacist-led transitions of care (TOC) after hospitalization for acute myocardial infarction (AMI) is examined. The real-world, single-center pre-post design compares outcomes before and after implementing a TOC service focused on medication reconciliation, patient education, and discharge optimization. The primary outcome was 90-day cardiovascular readmissions; secondary outcomes included 30-day cardiovascular and all-cause

en

0:02

Proton Pump Inhibitor Use and Incident Hypertension...

PACUPod: Cardiology ·

2025/09/03

en

7:36

Benefit and Harm of Intensive Blood Pressure Control...

PACUPod: Cardiology ·

2025/09/03

A concise episode summarizing a post hoc analysis of the STEP trial that investigates how baseline cardiovascular risk modifies the balance of benefits and harms of intensive blood pressure control in older hypertensive adults. We cover study design, key findings (overall reduction in cardiovascular events with intensive targets, modest non-significant rise in adverse events), risk-stratified results, practical targets (110–130 mm Hg vs 130–150 mm Hg), and implications for practice in

en

92 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown